This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Myasthenia Gravis
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
-
SFM Clinical Research, LLC, Boca Raton, Florida, United States, 33487
BayCare Health System, Inc. St Anthony's Hospital, St. Petersburg, Florida, United States, 33705
Prairie Education and Research Cooperative and HSHS Medical Group, O'Fallon, Illinois, United States, 62701
Norton Neuroscience Institute, Louisville, Kentucky, United States, 40241
National Neuromuscular Research Institute, Austin, Texas, United States, 78759
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
argenx,
2034-06